Inflammatory Gene Expression, Insulin Resistance, and Circulating Markers Vary by Visceral Adiposity in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. | Synapse
March 12, 2026
Inflammatory Gene Expression, Insulin Resistance, and Circulating Markers Vary by Visceral Adiposity in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.
Key Points
This research aims to explore how different levels of visceral adiposity affect inflammatory gene expression and insulin resistance in metabolic dysfunction-associated liver disease.
Analyzed gene expression related to inflammation.
Assessed insulin resistance in relation to visceral fat levels.
Evaluated circulating markers indicative of metabolic dysfunction.
Differential immune changes were observed across varying levels of visceral adiposity.
Insulin resistance correlated with specific inflammatory markers linked to adiposity profiles.
Abstract
These findings highlight differential immune changes across visceral adiposity levels in MASLD, supporting the need for tailored interventions based on adiposity profiles.